Quest’s BRCAvantage Widely Expands Patient Access to BRCA Genetic Testing for Inherited Breast, Ovarian Cancers
Quest also releases results from a national Harris survey revealing widespread confusion about BRCA testing.
Read MorePosted by Judy O'Rourke | Oct 15, 2013 | Breast, Cancer, Molecular Diagnostics, Unknown Origin & Other Cancer Types |
Quest also releases results from a national Harris survey revealing widespread confusion about BRCA testing.
Read MorePosted by Judy O'Rourke | Oct 8, 2013 | Cancer, Mass Spectrometry Reagents & Test Kits, Miscellaneous |
Improving the transfusion service’s ability to provide antigen-matched RBC units for alloimmunized patients.
Read MorePosted by Judy O'Rourke | Oct 4, 2013 | Uncategorized |
A range of products to explore, from bioMerieux’s new clinical mass spec MALDI-TOF-based system to new genetic tests for cancer, to bins to keep everything in its place.
Read MorePosted by Judy O'Rourke | Oct 3, 2013 | Molecular Diagnostics |
According to the patent application, would-be parents could specify "phenotypes of interest in the hypothetical offspring," and receive a report on the probabilities that using gametes from various providers would produce those traits. The traits men
Read MorePosted by Judy O'Rourke | Oct 2, 2013 | Cancer, Molecular Diagnostics |
Per this agreement, approximately 4.1 million members associated with more than 200 health insurers, self-funded employers, and other payors of health care services will be able to access Response Genetics’ suite of molecular predictive testing at a
Read More